A Phase 2 interventional study of Maralixibat and Placebo in Biliary Atresia, sponsored by Mirum Pharmaceuticals, Inc.. Completed at 22 sites in 8 countries. Open to participants aged 21 Days to 111 Days. Per ClinicalTrials.gov, last updated 2025-03-19.
Sponsored by Mirum Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Biliary Atresia with a site in United States — 8 open to participants now, 10 under way, 2 of them phase 3. Biliary Atresia · United States.
Among the 22 studies in Biliary Atresia with a site in United States, this one is the 7th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2021, is one of 4 in phase 2, and was the 17th registered.
77 studies on the registry are indexed under Biliary Atresia; 25 are open to participants now.
Browse Biliary Atresia studies →8 of the 22 studies in Biliary Atresia with a site in United States are open now. Recruiting first, the newest first:
University of Alabama at Birmingham · Sites in United States
Ages 2 wk–4 mo · Healthy volunteers
Boston Children's Hospital · Sites in United States
Ages 0 days–3 mo
Holterman, Ai-Xuan, M.D. · Sites in United States, Pakistan, Vietnam
Ages 14 days–180 days
University of Pittsburgh · Sites in United States
Sanford Health · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 21 Biliary Atresia studies recruiting now, 3 (14%) set no upper age limit and 18 (86%) stop at 75 or younger; 21 take children under 18; 6 take healthy volunteers.
This study: 21 Days to 111 Days · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 6 · Phase 3 3
First in 2000; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 75 is above the median of 45 across 43 interventional studies indexed under Biliary Atresia.
Median enrollment 53 across the 14 interventional studies, 776 across the 8 observational. Of the 11 that completed or were terminated, 5 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 22 have an industry lead sponsor. The 10 most frequent:
Mirum Pharmaceuticals, Inc. is the lead sponsor of 40 studies on the registry; 7 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 11 (92%) have results posted.
Mirum Pharmaceuticals, Inc. has 2 studies filed under Biliary Atresia — fewer than ten, so there is no comparison to draw.
1 of the studies in Biliary Atresia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07250854University of Alabama at BirminghamThe Use of Near-Infrared Fluorescence Cholangiography With Indocyanine Green (ICG) in the Work Up of Neonatal Cholestasis | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies in Biliary Atresia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A study to evaluate the efficacy and safety of maralixibat in infants with Biliary Atresia (BA) after Hepatoportoenterostomy (HPE, also known as the Kasai procedure).
This is a double-blind randomized, placebo-controlled study in subjects with Biliary Atresia with a primary endpoint at Week 26 followed by long-term open-label period during which all subjects will receive maralixibat to Week 104.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The double-blind period comprised of 4-8 weeks of dose escalation followed by 18 - 22 weeks of stable dosing treatment, after which participants were transferred to the open-label arm.
Drug: Maralixibat
The double-blind period comprised of 4-8 weeks of dose escalation followed by 18 - 22 weeks of stable dosing treatment, after which participants were transferred to the open-label arm.
Other: Placebo
The Open-Label period comprised of 4-8 weeks of dose escalation followed by 70 - 74 weeks of stable dosing treatment. During the OLE, all participants, regardless of treatment assignment in the double-blind period, received maralixibat.
Drug: Maralixibat
A small molecule inhibitor of the ileal bile acid transporter (IBAT)
Also known as: Formerly LUM001 and SHP625
Identical to maralixibat except for the active drug substance
Mean Change in Total Serum Bilirubin Levels
Time frame: From baseline to Week 26
Mean Change in Total Serum Bile Acids
Time frame: From baseline to Week 26
Proportion of Participants With Mean TSB Levels <2 mg/dL Through Week 26
Time frame: From baseline to Week 26
Proportion of Participants Observed to Have a Liver-related Clinical Event Transplantation, Liver Decompensation, Discontinuations Due to Liver Related Events, or Death.
Liver decompensation (hepatic encephalopathy, variceal bleeding, new persistent ascites)
Time frame: From Baseline to Week 26
Proportion of Participants Undergoing Liver Transplantation or Death
Time frame: From Baseline to Week 26
Proportion of Participants Observed to Develop Clinically Evident Portal Hypertension Defined as Splenomegaly and Thrombocytopenia (Platelet Count <150 x 109/L) or Clinically Evident Ascites or Endoscopic Evidence of Esophageal or Gastric Varices.
Splenomegaly =\> (spleen size \>2 cm below the costal margin palpated on physical examination)
Time frame: From Baseline to Week 26
Proportion of Participants With Mean TSB Levels ≤1.2 mg/dL
Time frame: From Baseline to Week 26
Proportion of Participants With Mean sBA Levels ≤40 mmol/L
Time frame: From Baseline to Week 26
A total of 75 participants were enrolled at 19 sites across 8 countries (China, Germany, Poland, Singapore, Taiwan, United Kingdom, United States, and Vietnam).
| Milestone | Double Blind - Maralixibat | Double Blind - Placebo | Open Label - Maralixibat |
|---|---|---|---|
| Started | 40 | 35 | 0 |
| Completed | 28 | 24 | 0 |
| Not completed | 12 | 11 | 0 |
| Withdrew: Consent withdrawal by subject | 2 | 1 | 0 |
| Withdrew: Adverse event | 5 | 3 | 0 |
| Withdrew: Liver transplant | 5 | 6 | 0 |
| Withdrew: Disease progression | 0 | 1 | 0 |
| Milestone | Double Blind - Maralixibat | Double Blind - Placebo | Open Label - Maralixibat |
|---|---|---|---|
| Started | 0 | 0 | 52 |
| Completed | 0 | 0 | 1 |
| Not completed | 0 | 0 | 51 |
| Withdrew: Drug interruption criteria | 0 | 0 | 1 |
| Withdrew: Liver transplant | 0 | 0 | 1 |
| Withdrew: Disease progression | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 3 |
| Withdrew: Study termination by sponsor | 0 | 0 | 45 |
| mg/dl | Double Blind - Maralixibat | Double Blind - Placebo |
|---|---|---|
| Mean Change in Total Serum Bilirubin Levels | -3.5 ± 0.853 | -3.11 ± 0.947 |
| umol/L | Double Blind - Maralixibat | Double Blind - Placebo |
|---|---|---|
| Mean Change in Total Serum Bile Acids | -51.19 ± 24.436 | -5.29 ± 28.440 |
| Participants | Double Blind - Maralixibat | Double Blind - Placebo |
|---|---|---|
| Proportion of Participants With Mean TSB Levels <2 mg/dL Through Week 26 | 24 | 20 |
Liver decompensation (hepatic encephalopathy, variceal bleeding, new persistent ascites)
| Participants | Double Blind - Maralixibat | Double Blind - Placebo |
|---|---|---|
| Proportion of Participants Observed to Have a Liver-related Clinical Event Transplantation, Liver Decompensation, Discontinuations Due to Liver Related Events, or Death. | 8 | 7 |
| Participants | Double Blind - Maralixibat | Double Blind - Placebo |
|---|---|---|
| Proportion of Participants Undergoing Liver Transplantation or Death | 5 | 3 |
Splenomegaly =\> (spleen size \>2 cm below the costal margin palpated on physical examination)
| Participants | Double Blind - Maralixibat | Double Blind - Placebo |
|---|---|---|
| Proportion of Participants Observed to Develop Clinically Evident Portal Hypertension Defined as Splenomegaly and Thrombocytopenia (Platelet Count <150 x 109/L) or Clinically Evident Ascites or Endoscopic Evidence of Esophageal or Gastric Varices. | 3 | 4 |
| Participants | Double Blind - Maralixibat | Double Blind - Placebo |
|---|---|---|
| Proportion of Participants With Mean TSB Levels ≤1.2 mg/dL | 23 | 18 |
| Participants | Double Blind - Maralixibat | Double Blind - Placebo |
|---|---|---|
| Proportion of Participants With Mean sBA Levels ≤40 mmol/L | 10 | 7 |
Collected over Baseline to EOT. In this study the longest time frame was 102.4 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double Blind - Maralixibat | 0/40 (0%) | 26/40 (65%) | 38/40 (95%) |
| Double Blind - Placebo | 0/35 (0%) | 25/35 (71.4%) | 33/35 (94.3%) |
| Open Label - Maralixibat | 0/52 (0%) | 21/52 (40.4%) | 47/52 (90.4%) |
| Event | Double Blind - Maralixibat | Double Blind - Placebo | Open Label - Maralixibat |
|---|---|---|---|
| CholangitisHepatobiliary disorders | 15/40 | 17/35 | 8/52 |
| PneumoniaInfections and infestations | 8/40 | 4/35 | 2/52 |
| COVID-19Infections and infestations | 1/40 | 3/35 | 0/52 |
| SepsisInfections and infestations | 0/40 | 2/35 | 0/52 |
| Hepatic enzyme increasedInvestigations | 2/40 | 0/35 | 1/52 |
| DiarrhoeaGastrointestinal disorders | 2/40 | 0/35 | 0/52 |
| BronchiolitisInfections and infestations | 2/40 | 1/35 | 1/52 |
| Parainfluenzae virus infectionInfections and infestations | 2/40 | 0/35 | 0/52 |
| Adenovirus infectionInfections and infestations | 0/40 | 0/35 | 2/52 |
| GastroenteritisInfections and infestations | 0/40 | 0/35 | 2/52 |
| Event | Double Blind - Maralixibat | Double Blind - Placebo | Open Label - Maralixibat |
|---|---|---|---|
| PyrexiaGeneral disorders | 14/40 | 8/35 | 12/52 |
| DiarrhoeaGastrointestinal disorders | 13/40 | 8/35 | 13/52 |
| Vitamin D deficiencyMetabolism and nutrition disorders | 7/40 | 9/35 | 8/52 |
| Upper respiratory tract infectionInfections and infestations | 7/40 | 3/35 | 12/52 |
| CoughRespiratory, thoracic and mediastinal disorders | 8/40 | 5/35 | 8/52 |
| Vitamin A deficiencyMetabolism and nutrition disorders | 3/40 | 7/35 | 3/52 |
| VomitingGastrointestinal disorders | 4/40 | 6/35 | 2/52 |
| CholangitisHepatobiliary disorders | 6/40 | 6/35 | 3/52 |
| EczemaSkin and subcutaneous tissue disorders | 6/40 | 4/35 | 1/52 |
| PneumoniaInfections and infestations | 6/40 | 5/35 | 5/52 |
| Age, Customized(participants) | Double Blind Period - Placebo | Double Blind - Maralixibat | Total |
|---|---|---|---|
| Infants and toddlers (28 days-23 months) | 35 | 40 | 75 |
| Sex: Female, Male(Participants) | Double Blind Period - Placebo | Double Blind - Maralixibat | Total |
|---|---|---|---|
| Female | 15 | 21 | 36 |
| Male | 20 | 19 | 39 |
| Race/Ethnicity, Customized(Participants) | Double Blind Period - Placebo | Double Blind - Maralixibat | Total |
|---|---|---|---|
| Race — Asian | 28 | 31 | 59 |
| Race — White | 5 | 8 | 13 |
| Race — More than one race | 0 | 1 | 1 |
| Race — Not Reported | 1 | 0 | 1 |
| Race — Other | 1 | 0 | 1 |
| Region of Enrollment(Participants) | Double Blind Period - Placebo | Double Blind - Maralixibat | Total |
|---|---|---|---|
| Vietnam | 8 | 9 | 17 |
| Singapore | 0 | 1 | 1 |
| United States | 1 | 4 | 5 |
| China | 18 | 18 | 36 |
| Taiwan | 1 | 2 | 3 |
| Poland | 1 | 1 | 2 |
| United Kingdom | 6 | 4 | 10 |
| Germany | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2021 to primary completion in Nov 2023, 27 months.
Results were first posted in Feb 2025, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Maralixibat